House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
AHA urges Congress to support physicians, access to care in statement for House subcommittee hearing
The AHA provided a statement Feb. 24 for a House Ways and Means Health Subcommittee hearing titled “Advancing the Next Generation of America’s Health Care…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…
Headline
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir,…
Perspective
Abraham Lincoln, among those whose legacy we honor with Presidents Day next week, might have put it this way: Thirteen score and three days from now… …
Headline
The Senate Special Committee on Aging held a hearing Feb. 11 on issues impacting physician burnout. The AHA provided a statement for the hearing and urged…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…